Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by FredTheVoiceon Jun 27, 2020 8:25am

261 Views

Post# 31198376

RE:Price

Go back just before TROGARZO approval........you will read the same questionning about TH on this board.....

SPCEO and others were saying to be patient. That the story was strong.

And we are at the same place waiting for NASH PHASE III to be confirmed.

And PHASE I for oncology.

In september, october, we will be writing about how the stock price is maybe to high........"well 23 $ is a lot...........prepare for a breakdown......".

FTV.

Bullboard Posts

Changing Europe’s dependency on HREE from China